Ovarian hyperstimulation syndrome in gonadotropin-treated laboratory South African clawed frogs (Xenopus laevis)

Journal of the American Association for Laboratory Animal Science

Volumn 46, Issue 3, 2007, Pages 64-67

  Green, Sherril L ^a   Parker, John ^b   Davis, Corrine ^a   Bouley, Donna M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; SERIC GONADOTROPIN; VASCULOTROPIN;

ANIMAL ANATOMY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL USE; ARTICLE; ASCITES; DIFFERENTIAL DIAGNOSIS; EDEMA; FEMALE; GRANULOSA CELL; HEART; LIVER; NONHUMAN; OVARY HYPERSTIMULATION; OVARY HYPERTROPHY; RISK FACTOR; THECA CELL; XENOPUS LAEVIS;

ANIMALS; CHORIONIC GONADOTROPIN; FEMALE; OOCYTES; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; XENOPUS LAEVIS;

ANURA; XENOPUS LAEVIS;

EID: 34447517284     PISSN: 15596109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Agrawal R, Tan SL, Wild S, Sladkevicius P, Engmann L, Payne N, Bekir J, Campbell S, Conway G, Jacobs H. 1999. Serum vascular endothelial growth factor concentration in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 71:287-293.
2. Al-Shawaf T, Grudzinskas JG. 2003. Prevention and treatment of ovarian hyperstimulation syndrome. Best Prac Res Clin Obstet Gynaec 17:249-261.
3. Artini PG, Fasciani A, Monti M, Luisi S, D'Ambrogio G, Genazzani AR. 1998. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertil Steril 70:560-564.
4. Beerendonk CCM, van Dop PA, Braat DDM, Merkus JMWM. 1998. Ovarian hyperstimulation syndrome: facts and fallacies. Obstet Gynecol Survey 53:439-449.
5. Budev MM, Arroliga AC, Falcone T. 2005. Ovarian hyperstimulation syndrome. Crit Care Med 33(10 Suppl):S301-S306.
6. Casper RF. 1996. Ovarian hyperstimulation: effects of GnRH analogues. Does triggering ovulation with gonadotrophin-releasing hormone analogue prevent severe ovarian hyperstimulation syndrome? Hum Reprod 11:1144-1146.
7. Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. 2000. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 15:1037-1042.
8. Chen D, Burmeister L, Goldschlag D, Rosenwaks Z. 2003. Ovarian hyperstimulation syndrome: strategies for prevention. Reprod Biomed Online 7:43-49.
9. Delvigne A, Rozenberg S. 2002. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reprod Update 8:559-577.
10. Delvigne A, Rozenberg S. 2002. Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome. Int J Fertil 47:21-226.
11. Delvigne A, Rozenberg S. 2003. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Human Reprod Update 9:77-96.
12. Enskog A, Henrikkson M, Unander M, Nilsson L, Brannstrom M. 1999. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 71:808-814.
13. Garcia-Velasco JA, Pellicer A. 2003. New concepts in the understanding of the ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol 15:251-255.
14. Green SL, Bouley DM, Tolwani RJ, Waggie KS, Lifland BD, Otto GM, Ferrell JEJ. 1999. Identification and management of an outbreak of Flavobacterium meningosepticum infection in a coelomicony of South African clawed frogs (Xenopus laevis). J Am Vet Med Assoc 214:1833.
15. Hitkari JA, Rowe TP, von Dadelszen P. 2006. Activated protein C and the ovarian hyperstimulation syndrome: possible therapeutic implications. Med Hypotheses 66:929-933.
16. Keem K, Smith LD, Wallace RA, Wolf D. 1979. Growth rate of oocytes in laboratory maintained Xenopus laevis. Gamete Res 2:125-135.
17. Levin ER, Rosen GF, Cassidenti DL, Yee B, Meldrum D, Wisot A, Pedram A. 1998. Role of vascular endothelial growth factor in ovarian hyperstimulaiton syndrome. J Clin Invest 102:1978-1985.
18. Mathur R, Jenkins J. 2001. Ovarian hyperstimulation syndrome: an endocrinopathy? Curr Opin Obstet Gynecoelomic 13:329-333.
19. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. 2000. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 73:901-907.
20. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV Jr, Connolly DT, Robertson DM. 1994. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344:235-236.
21. Morris RS, Paulson RJ, Sauer MV, Lobo RA. 1995. Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Human Reprod 10:811-814.
22. Reljic M, Vlaisavljevic V, Gavricx V. 1999. Number of oocytes retrieved and resulting pregnancy. Risk factors for ovarian hyperstimulation syndrome. J Reprod Med 44:713-718.
23. Sive HL, Grainger RM, Harland RM. 2000. Obtaining embryos, p 91-101. In: Sive HL, Grainger RM, Harland RM, editors. Early development of Xenopus laevis: a laboratory manual. New York: Cold Spring Harbor Laboratory Press.
24. Wu M, Gerhart J. 1991. Raising Xenopus in the laboratory. Methods Cell Biol 36:3-18.